Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,48%
1 067,54
+5,14
+0,48%
—1 062,401 064,141 071,991 061,02——
SIXC
Communications
SIXC
Communications
SIXC
-0,23%
605,35
-1,39
-0,23%
—606,74606,74609,84603,82——
SIXE
Energy
SIXE
Energy
SIXE
+0,11%
1 239,58
+1,37
+0,11%
—1 238,211 236,601 246,411 232,10——
SIXI
Industrials
SIXI
Industrials
SIXI
+1,16%
1 738,57
+19,96
+1,16%
—1 718,611 723,231 741,481 717,47——
SIXM
Financials
SIXM
Financials
SIXM
+0,64%
641,45
+4,08
+0,64%
—637,37638,27642,30638,27——
SIXR
Staples
SIXR
Staples
SIXR
+0,14%
854,77
+1,18
+0,14%
—853,59854,05858,19851,34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,13%
218,62
+0,29
+0,13%
—218,33218,33219,73217,15——
SIXT
Technology
SIXT
Technology
SIXT
+1,58%
3 651,52
+56,71
+1,58%
—3 594,813 620,103 657,473 615,34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,64%
914,33
+5,79
+0,64%
—908,54909,50917,35907,07——
SIXV
Health care
SIXV
Health care
SIXV
+1,25%
1 513,66
+18,66
+1,25%
—1 495,001 499,611 517,101 499,61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,89%
2 419,75
+21,44
+0,89%
—2 398,312 406,822 421,802 405,28——
ALNOV:EPA
Novacyt SA
0,58 €
+0,87%
(+0,0050) 1D
22-май, 17:39:31 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNOV...
Open
0,61 €
High
0,62 €
Low
0,55 €
Mkt. cap
42,50 млн
Avg. vol.
2,07 млн
Volume
2,11 млн
52-wk high
1,04 €
52-wk low
0,29 €
EPS
-0,38 €
Shares outstanding
72,59 млн
No. of employees
216
News stories
From sources across the web
Investing.com Nigeria
Investing.com Nigeria
·
10 саат мурун
Novacyt schedules annual meeting for June 30 By Investing.com
TipRanks
TipRanks
·
11 саат мурун
Novacyt sets June date for in-person AGM and online investor presentation
Investegate
Investegate
·
11 саат мурун
Notice of AGM
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees216
Founded2006-ж., 3-июл.
Headquarters-
Sector-
Websitenovacyt.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
4,90 млн
4,90 млн
5,12 млн
5,12 млн
Cost of goods sold
1,64 млн
1,64 млн
2,06 млн
2,06 млн
Cost of revenue
1,64 млн
1,64 млн
2,06 млн
2,06 млн
Research and development expenses
1,02 млн
1,02 млн
1,03 млн
1,03 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,51 млн
5,51 млн
5,24 млн
5,24 млн
Operating expense
6,43 млн
6,43 млн
14,13 млн
14,13 млн
Total operating expenses
8,08 млн
8,08 млн
16,19 млн
16,19 млн
Operating income
-3,18 млн
-3,18 млн
-11,07 млн
-11,07 млн
Other non operating income
-31,00 миң
-31,00 миң
2,67 млн
2,67 млн
EBT including unusual items
-3,51 млн
-3,51 млн
-10,16 млн
-10,16 млн
EBT excluding unusual items
-3,12 млн
-3,12 млн
-10,55 млн
-10,55 млн
Income tax expense
-133,50 миң
-133,50 миң
-1,81 млн
-1,81 млн
Effective tax rate
3,80%
3,80%
17,85%
17,85%
Other operating expenses
-97,50 миң
-97,50 миң
7,86 млн
7,86 млн
Net income
-3,17 млн
-3,17 млн
-8,27 млн
-8,27 млн
Net profit margin
-64,76%
-64,76%
-161,60%
-161,60%
Earnings per share
-
-
-
-
Interest and investment income
177,00 миң
177,00 миң
-
-
Interest expense
-154,00 миң
-154,00 миң
-2,09 млн
-2,09 млн
Net interest expenses
23,00 миң
23,00 миң
-2,09 млн
-2,09 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,17 млн
-2,17 млн
-2,80 млн
-2,80 млн
Gain or loss from assets sale
-147,50 миң
-147,50 миң
-3,00 миң
-3,00 миң
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer